Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,055 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Multicenter phase II study of biweekly CAPIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study).
Suzuki N, Hazama S, Nagasaka T, Tanioka H, Iwamoto Y, Negoro Y, Yamauchi M, Kobayashi M, Okuda H, Fujishima N, Nishimura T, Yamanaka N, Toyota K, Mori Y, Nakagami Y, Shimokawa M, Nagano H, Okajima M. Suzuki N, et al. Among authors: okuda h. Int J Clin Oncol. 2019 Oct;24(10):1223-1230. doi: 10.1007/s10147-019-01473-3. Epub 2019 May 29. Int J Clin Oncol. 2019. PMID: 31144145 Free PMC article. Clinical Trial.
A prospective feasibility study of uracil-tegafur and leucovorin as adjuvant chemotherapy for patients aged ≥ 80 years after curative resection of colorectal cancer, the HiSCO-03 study.
Okuda H, Shimomura M, Ikeda S, Nakahara M, Miguchi M, Ishizaki Y, Saitoh Y, Toyota K, Sumitani D, Shimizu Y, Takakura Y, Shimizu W, Yoshimitsu M, Kodama S, Fujimori M, Oheda M, Kobayashi H, Ohdan H; Hiroshima Surgical Study Group of Clinical Oncology (HiSCO). Okuda H, et al. Cancer Chemother Pharmacol. 2023 Apr;91(4):317-324. doi: 10.1007/s00280-023-04526-7. Epub 2023 Mar 22. Cancer Chemother Pharmacol. 2023. PMID: 36947210 Clinical Trial.
1,055 results